Oxaliplatin is used as part of FOLFOX to treat colorectal cancer (CRC). Oxaliplatin produces chemotherapy-induced peripheral neuropathy (OIPN). We report that controlled-release oxycodone (CR oxycodone) attenuates the pain of OIPN and extendes FOLFOX. We investigate the efficacy of CR oxycodone for OIPN and its association with patients’ survival time.
Stage III or IV CRC were included in this study. All patients underwent surgery to extirpate the primary CRC and received FOLFOX. Patients administered CR oxycodone were defined as OXY group, and those who did not receive CR oxycodone were defined as non-OXY group. Incidence and severity of OIPN and the number of FOLFOX cycles were measured. Neurological toxicities were assessed according to the CTCAE version 3.0. Survival time was calculated using the Kaplan-Meier method.
All patients had OIPN. Grade 3 sensory neuropathy was observed in 2 patients in the non-OXY group. FOLFOX therapy was discontinued in 10 patients of the non-OXY group due to severe OIPN. The median number of FOLFOX cycles in the OXY and non-OXY groups was 13 and 7 respectively (P <0.05). The median value of cumulative oxaliplatin dose was 1072.3 mg/m2 in the OXY group and 483.0 mg/m2 in the non-OXY group (P <0.05). Patients in the OXY group had relatively longer survival than those in the non-OXY group (median survival, 58 months vs. 36 months; P=0.06).
CR oxycodone may attenuate the severity of OIPN and extend FOLFOX therapy. CR oxycodone for OIPN might be relatively effective for better patient compliance with FOLFOX, and longer survival.